Abatacept shortage hits earlier than forecast


Pharmacists urged to advise patients with prescriptions for Orencia (abatacept) to speak to their specialists as shortages hit  Bristol-Myers Squibb Australia (BMS) has advised the Therapeutic Goods Administration (TGA) that both its Orencia 125mg/mL ClickJect autoinjector and prefilled syringe subcutaneous products are now in short supply.  The company had previously anticipated that shortages to the

This content is restricted to registered users only. If you have already registered on the AJP website please login below, Or you can Register for free.

Forgot Password?Why do I need to login & stay in?

Previous EBOS eyes TerryWhite expansion
Next Will Sigma’s ASX 200 debut change investor outlook?